Business and Finance

The financial decision is due to customer demand stemming from the reshoring of drug supply services.

The President plans to sign an executive order on Monday morning to enforce the trade clause.

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

The company’s branded form of nadofaragene firadenovec-vncg will also be produced at a hub in Parsippany, NJ.

The deal for the San Diego hub provides the CDMO with its first-ever North American manufacturing location for prefilled syringes and cartridges.

One expert's take on reshoring pharma manufacturing services in the US amid likely tariffs to drugs looming.

A panel discussion uncovers ways to deliver personalized therapy ops in a timely fashion.

How data-driven insights can help pharma companies balance their revenue management and innovation strategies—including resource allocation, pricing, and market access.

The parties aim to create an end-to-end digital thread that links research data all the way through to life sciences manufacturing.

In a move meant to encourage domestic production, the president’s executive order features a 10% baseline tax, expected to take effect April 9.

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a month, while Lilly also sells the GLP-1 via its LillyDirect platform.

CRYOPDP—centered around clinical trials, biopharma, and cell and gene therapies—augments DHL’s specialty pharma logistics expertise.

The move by the CDMO—who also houses a North American HQ in Indiana—expresses its interest in providing compliant storage and logistics solutions globally.

The Beijing location represents the sixth worldwide.

What drivers impact the differences in expenditures?

Why having these strategies for results—amid disruptions—will be critical to success.

The thermal packaging company not only bolsters its APAC presence—it also grows its influence in the life sciences’ temperature-monitoring logistics sector.

The CRDMO’s acquisition of the Baltimore plant is expected to boost its biologics presence.

The partnership focuses on enhancing the patient experience by providing greater affordability and access to specialty meds.

The updated tax on Canadian imports will rise from 25% to 50%, taking effect March 12.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jason C. Foster, CEO of Ori Biotech, offers his perspective on the state of CGTs, along with their potential for transforming medicine.

This link in the pharma supply chain is undergoing a major transformation propelled by technological advancements, regulatory changes, and evolving market dynamics, requiring industry leaders to adopt innovative strategies in order to remain competitive.

The US president delays tariffs that comply with the 2020 USMCA for one month, with reciprocal tariffs still expected to go into effect by April 2.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Tom Dorsett, CEO, RazorMetrics, describes how the software company’s solution can help deliver better patient outcomes and substantial savings for healthcare plans, employers, and members alike.

The agreement—powered by YASKAWA's Maholo robot—aims to address challenges in production and commercialization while offering access to academic and startup communities.

NovoCare will offer the GLP-1 injection to cash-paying patients for a discounted $499 per month.

The 25% tax on various imports have gone into effect, resulting in retaliatory tariffs from the impacted nations.

After an initial 30-day pause, the US president plans to re-enact the import taxes on the nation’s trading partners—while also doubling the 10% tariff on China.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, describes how the tariffs can affect price or competition within the branded drug space.

The presidential action follows up on a 2019 final rule aimed at empowering patients and boosting competition among hospitals, group health plans, and health insurance issuers in both individual and group markets.